Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves
Source: SeekingAlpha
2026-03-06 08:28:08 ET
More on Thermo Fisher Scientific, Arcutis Biotherapeutics, etc.
- Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
- Elanco Animal Health Incorporated (ELAN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Thermo Fisher Scientific: Recovery In Life Sciences Solutions
- Masimo Q4 2025 Earnings Preview
- Elanco targets $1.15B innovation revenue in 2026 as Big 6 launches gain momentum
Read the full article on Seeking Alpha
For further details see:
Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves
Arcutis Biotherapeutics Inc.
NASDAQ: ARQT
ARQT Trading
3.8% G/L:
$24.475 Last:
346,296 Volume:
$23.92 Open:
ARQT Latest News
March 05, 2026 09:00:00 am
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
March 03, 2026 08:00:00 am
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
February 27, 2026 04:00:00 pm
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference
ARQT Stock Data
$3,301,042,082
98,483,722
0.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
Westlake Village
